NPPB and hydrops fetalis: Notably, in an exploratory analysis of the efficacy and safety of sacubitril/valsartan according to dose level achieved in the PIONEER‐HF trial,33 the proportional reduction in NT‐proBNP concentration from baseline to Week 8 was consistent regardless of dose level (OR: 0.72, 95% CI: 0.58–0.88, p = .67).